CLEC9A Protein (AA 57-264) (Fc Tag)

N° du produit ABIN7274367

Détail du produit

Antigène: CLEC9A (C-Type Lectin Domain Family 9, Member A (CLEC9A))

Type de proteíne: Recombinant

Attributs du protein: AA 57-264

Origine: Souris

Source: HEK-293 Cells

Purification/Conjugué: Cette CLEC9A protéine est marqué à la Fc Tag.

Fonction: Mouse CLEC9A Protein

Séquence: Lys57-Ile264

Attributs du produit: Recombinant Mouse CLEC9A Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Lys57-Ile264.

Pureté: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Stérilité: 0.22 μm filtered

niveau d'endotoxine: Less than 1EU per μg by the LAL method.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Stock: -20 °C,-80 °C

Stockage commentaire: -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Date de péremption: 12 months

Détail du antigène

Antigène: CLEC9A (C-Type Lectin Domain Family 9, Member A (CLEC9A))

Autre désignation: CLEC9A (CLEC9A Produits)

Synonymes: 9830005G06Rik Protein, DNGR-1 Protein, DNGR1 Protein, UNQ9341 Protein, RGD1562513 Protein, C-type lectin domain family 9, member a Protein, C-type lectin domain containing 9A Protein, C-type lectin domain family 9, member A Protein, Clec9a Protein, CLEC9A Protein

Sujet: CLEC9A expression was significantly higher in psoriatic skin compared with healthy donor. In psoriatic skin and PsA ST, CLEC9A() cells were in close proximity to TUNEL() cells. SF CLEC9A levels were significantly lower compared with paired PsA serum. Adalimumab treatment did not affect CLEC9A serum level and skin expression. The downregulation of synovial CLEC9A might be associated with a novel mechanism by which anti-TNF therapy might reduce CD8-mediated inflammation in PsA patients.

Poids moléculaire: 50.9 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.

NCBI Accession: NP_001192292